Axsome Therapeutics reaches agreement to dismiss patent litigation with Sandoz
…
94,320$
3,04%
Echtzeit-Aktienkurs Axsome Therapeutics Inc.
Bid:
Ask:
Nachrichten zur Axsome Therapeutics Inc. Aktie
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Aug. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
Axsome Therapeutics (AXSM) Q2 2024 Earnings Call Transcript
AXSM earnings call for the period ending June 30, 2024.…
Axsome Therapeutics, Inc. (AXSM) Q2 2024 Earnings Call Transcript
…
Axsome Therapeutics Q2 2024 Earnings Preview
…
Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and…
5 Biggest Pharmaceutical ETFs in 2024
The global pharmaceutical market reached a total value of US$1.6 trillion in 2023, according to Statista, up significantly from the…
Axsome Therapeutics (AXSM) Q1 2024 Earnings Call Transcript
AXSM earnings call for the period ending March 31, 2024.…
Axsome Therapeutics, Inc. (AXSM) Q1 2024 Earnings Call Transcript
…
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, April 12, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and…
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
AXS-12 statistically significantly reduced cataplexy attacks compared to placebo (p=0.018, primary endpoint)…
Earnings call: Axsome Therapeutics reports solid growth in 2023 By Investing.com
Earnings call: Axsome Therapeutics reports solid growth in 2023…
Axsome Therapeutics, Inc. (AXSM) Q4 2023 Earnings Call Transcript
…
Axsome Therapeutics (AXSM) Q4 2023 Earnings Call Transcript
AXSM earnings call for the period ending December 31, 2023.…
Axsome Therapeutics a new outperform at RBC on underappreciated pipeline
…
Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today
NEW YORK, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and…
Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Axsome Therapeutics, Inc. (AXSM) Investors of Class Action and Encourages Shareholders to Contact the Firm
NEW YORK, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC a nationally…
Axsome Therapeutics, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; December 7, 2023 deadline.
Investors can contact the law firm at no cost to learn more about recovering their losses…
Global Sleep Apnea Oral Appliances Market Size Worth USD 1.55 Billion By 2032 | CAGR of 13.2%
The Global Sleep Apnea Oral Appliances Market Size was valued at USD 0.45 Billion in 2022 and the Worldwide Sleep…
AXSM DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action – AXSM
NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
AXSM FINAL DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action – AXSM
NEW YORK, Nov. 24, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7
NEW YORK, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and…
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action – AXSM
NEW YORK, Nov. 17, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
Axsome Therapeutics: Costs Outpacing Auvelity Growth (Rating Downgrade)
…
Axsome Therapeutics (AXSM) Q3 2023 Earnings Call Transcript
AXSM earnings call for the period ending September 30, 2023.…
Axsome Therapeutics, Inc. (AXSM) Q3 2023 Earnings Call Transcript
…
Axsome Therapeutics Q3 2023 Earnings Preview
…
Axsome Therapeutics to Present at Upcoming Investor Conferences
NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and…
Axsome Therapeutics Presents Results of the ACCORD trial of AXS-05 in Alzheimer’s Disease Agitation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Conference
NEW YORK, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and…
Axsome Therapeutics Joins the Global Narcolepsy Community in Raising Awareness on World Narcolepsy Day
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and…
Why did Axsome Therapeutics stock go up today? Street analyst bullish
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
BofA upgrades Axsome to neutral, cites improved outlook for MDD drug
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K Axsome Therapeutics, For: Aug 15
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Axsome (AXSM) Q2 Earnings Beat, Stock Dips on Pipeline Updates
Axsome (AXSM) incurs a narrower-than-expected loss in the second quarter. The company provides updates on its central nervous system candidates....…
Axsome Therapeutics (AXSM) Q2 2023 Earnings Call Transcript
AXSM earnings call for the period ending June 30, 2023....…
Axsome Therapeutics (AXSM) Reports Q2 Loss, Tops Revenue Estimates
Axsome (AXSM) delivered earnings and revenue surprises of 19.35% and 16.21%, respectively, for the quarter ended June 2023. Do the…
Axsome Therapeutics GAAP EPS of -$1.54 misses by $0.30, revenue of $46.01M beats by $5.06M
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
Total 2Q 2023 product revenue of $46.7 million...…
Form 8-K Axsome Therapeutics, For: Aug 04
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Axsome Therapeutics Q2 2023 Earnings Preview
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Axsome Therapeutics to Report Second Quarter 2023 Financial Results on August 7
Axsome to host conference call and webcast on Monday, Aug. 7, 2023, at 8:00 a.m. Eastern Time Axsome to host…
Axsome (AXSM) Doses First Patient in Late-Stage ADHD Study
Axsome (AXSM) doses its first patient in the late-stage, label expansion study of solriamfetol for treating attention deficit hyperactivity disorder....…
Form 8-K Axsome Therapeutics, For: Jul 07
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults
NEW YORK, July 07, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and…
Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common Stock
NEW YORK, June 30, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (“Axsome” or the “Company”), a…
Axsome (AXSM) Down on Public Offering of Common Stock
Axsome (AXSM) is set to issue secondary shares, which will significantly dilute its current shareholder base. Consequently, share price declines....…